A comparison of biphasic insulin aspart (biasp30) with biphasic human insulin (bhi30) for type 2 diabetes mellitus in real clinical practice: A systematic review and meta-analysis

A comparison of biphasic insulin aspart (biasp30) with biphasic human insulin (bhi30) for type 2 diabetes mellitus in real clinical practice: A systematic review and meta-analysis

2013 Value in health

Wojciechowski, P. | Gaweska, M. | Caban, A. | Jurkiewicz, B. | Plisko, R. | Rys, P. | Volume: 16, Issue: 3, Pages: A157, Diabetes Mellitus, Insulin, Meta-analysis, systematic review, Value, Clinical Trials, analysis, Safety,

Both biphasic human insulin 30 (BHI30) and biphasic insulin aspart (BIAsp30) serve an effective treatment option in patients with T2DM and their relative efficacy has been investigated in randomized clinical trials (RCTs). The aim of our analysis was to compare efficacy and safety of BIAsp30 with BHI30 on the basis of non-interventional trials.

https://www.doi.org/10.1016/j.jval.2013.03.781; 10.1016/j.jval.2013.03.781